New HIV preventive strategy sparks excitement and protests at AIDS conference
The new HIV prevention treatment, lenacapavir injection, showed 100% efficacy in early trials, offering an alternative to daily pills like Truvada for prevention efforts.
Injectable HIV medication: What you need to know DW 07/19/2024
Injectable cabotegravir offers a new option in HIV prevention and treatment.
More good news about the twice-yearly PrEP injection - Queerty
Lenacapavir, a new injectable PrEP, shows promising effectiveness in trials, particularly for populations previously underserved by existing medications.
A Fading Weapon in the H.I.V. Fight: Condoms
Decline in condom use among gay and bisexual men, especially young and Hispanic individuals
Public health focus on PrEP may have overshadowed condom promotion
An "ultra" PrEP injection just three times a year could be on the way
Approval of new PrEP injection with potentially longer dosing intervals
Results of trial for cabotegravir ultra long-acting formulation presented at CROI 2024
New HIV preventive strategy sparks excitement and protests at AIDS conference
The new HIV prevention treatment, lenacapavir injection, showed 100% efficacy in early trials, offering an alternative to daily pills like Truvada for prevention efforts.
Injectable HIV medication: What you need to know DW 07/19/2024
Injectable cabotegravir offers a new option in HIV prevention and treatment.
More good news about the twice-yearly PrEP injection - Queerty
Lenacapavir, a new injectable PrEP, shows promising effectiveness in trials, particularly for populations previously underserved by existing medications.
A Fading Weapon in the H.I.V. Fight: Condoms
Decline in condom use among gay and bisexual men, especially young and Hispanic individuals
Public health focus on PrEP may have overshadowed condom promotion
An "ultra" PrEP injection just three times a year could be on the way
Approval of new PrEP injection with potentially longer dosing intervals
Results of trial for cabotegravir ultra long-acting formulation presented at CROI 2024
September 27 Is National Gay Men's HIV/AIDS Awareness Day
Despite overall declines in new HIV infections among gay and bisexual men, disparities remain significant, necessitating focused efforts on equitable access to prevention and treatment.
Over 1,000 on Dublin clinic's waiting list for HIV-prevention drug PrEP
There are significant delays in providing access to HIV Pre-Exposure Prophylaxis (PrEP) services, despite its proven effectiveness in reducing HIV infection risk.
September 27 Is National Gay Men's HIV/AIDS Awareness Day
Despite overall declines in new HIV infections among gay and bisexual men, disparities remain significant, necessitating focused efforts on equitable access to prevention and treatment.
Over 1,000 on Dublin clinic's waiting list for HIV-prevention drug PrEP
There are significant delays in providing access to HIV Pre-Exposure Prophylaxis (PrEP) services, despite its proven effectiveness in reducing HIV infection risk.
Black Women and Pre-Exposure Prophylaxis: Closing the Gap in HIV Prevention - Non Profit News | Nonprofit Quarterly
Black cisgendered women are less likely to take or be prescribed PrEP, a medication that helps prevent new HIV infections.
The Eboni research project aims to increase PrEP uptake among cisgendered Black women through education campaigns and training for healthcare providers.
Stigma, racism, and non-inclusive marketing are some of the barriers that contribute to lower PrEP usage among cisgendered Black women.
PrEP: Preventative HIV drug highly effective, study says
PrEP, a drug that prevents HIV infection, has been confirmed as highly effective in a real-world study.
The study found that PrEP reduced the chances of getting HIV by 86%, with clinical trials suggesting 99% effectiveness.
The Terrence Higgins Trust calls for easier access and increased awareness of PrEP, particularly among minority groups.
Black Women and Pre-Exposure Prophylaxis: Closing the Gap in HIV Prevention - Non Profit News | Nonprofit Quarterly
Black cisgendered women are less likely to take or be prescribed PrEP, a medication that helps prevent new HIV infections.
The Eboni research project aims to increase PrEP uptake among cisgendered Black women through education campaigns and training for healthcare providers.
Stigma, racism, and non-inclusive marketing are some of the barriers that contribute to lower PrEP usage among cisgendered Black women.
PrEP: Preventative HIV drug highly effective, study says
PrEP, a drug that prevents HIV infection, has been confirmed as highly effective in a real-world study.
The study found that PrEP reduced the chances of getting HIV by 86%, with clinical trials suggesting 99% effectiveness.
The Terrence Higgins Trust calls for easier access and increased awareness of PrEP, particularly among minority groups.